A phase I/IIa study of CAN-04 for the treatment of non-small cell lung cancer and pancreatic cancer.

Trial Profile

A phase I/IIa study of CAN-04 for the treatment of non-small cell lung cancer and pancreatic cancer.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs CAN 04 (Primary)
  • Indications Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CANFOUR
  • Most Recent Events

    • 21 Jul 2017 According to a Cantargia media release, clinical trial application for this trial has been approved by the regulatory authorities as well as the ethics committees in Denmark and Norway. The review is ongoing in additional countries.
    • 08 May 2017 This trial is expected to begin in June 2017, according to a Cantargia media release.
    • 20 Sep 2016 According to Cantargia media release, presentation of the phase I data is planned about a year after the start of the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top